Connor, Clark & Lunn Investment Management (CC&L)’s SYNAGEVA BIOPHARMA CORP COM STK (DE) GEVA Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio GEVA Stock Details GEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-6,500	Closed	-$603K	–	653
2014 Q4	$603K	Buy	6,500 +700	+12%	+$55.2K	﹤0.01%	364
2014 Q3	$399K	Buy	+5,800	New	+$415K	﹤0.01%	420

Other funds holding GEVA

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

CWAM

Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s GEVA Position: Q1 2015 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) in Q1 2015, closing a stake of 6,500 shares — an estimated $603K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in GEVA in Q3 2014 and held it in 2 quarters. The position peaked at $603K in Q4 2014. 130 funds tracked by Wall St. Rank hold GEVA as of Q1 2015.

Connor, Clark & Lunn Investment Management (CC&L) reported no remaining SYNAGEVA BIOPHARMA CORP COM STK (DE) position as of Q1 2015 after selling out during the quarter.
Connor, Clark & Lunn Investment Management (CC&L) sold 6,500 SYNAGEVA BIOPHARMA CORP COM STK (DE) shares in Q1 2015, an estimated $603K.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q3 2014 and held it in 2 quarters.
Connor, Clark & Lunn Investment Management (CC&L)'s SYNAGEVA BIOPHARMA CORP COM STK (DE) position peaked at $603K in Q4 2014.
130 funds tracked by Wall St. Rank held SYNAGEVA BIOPHARMA CORP COM STK (DE) as of Q1 2015.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q1 2015, filed 14 May 2015.